Myasthenie und Schwangerschaft

Myasthenie und Schwangerschaft

Kohorte DMGKW

Links und Quellen

Unter diesen Internetadressen finden Sie weitere nützliche Hinweise zum Thema Myasthenia gravis:

 

  • Zitierte Literatur
    1. Batocchi AP, Majolini L, Evoli A, Lino MM, Minisci C, Tonali P. Course and treatment of myasthenia gravis during pregnancy. Neurology. 1999;52(3):447-52.
    2. Plauche WC. Myasthenia gravis in mothers and their newborns. Clinical obstetrics and gynecology. 1991;34(1):82-99.
    3. Djelmis J, Sostarko M, Mayer D, Ivanisevic M. Myasthenia gravis in pregnancy: report on 69 cases. European journal of obstetrics, gynecology, and reproductive biology. 2002;104(1):21-5.
    4. Hoff JM, Daltveit AK, Gilhus NE. Myasthenia gravis: consequences for pregnancy, delivery, and the newborn. Neurology. 2003;61(10):1362-6.
    5. Benshushan A, Rojansky N, Weinstein D. Myasthenia gravis and preeclampsia. Israel journal of medical sciences. 1994;30(3):229-33.
    6. Ozcan J, Balson IF, Dennis AT. New diagnosis myasthenia gravis and preeclampsia in late pregnancy. BMJ case reports. 2015;2015.
    7. Lake AJ, Al Khabbaz A, Keeney R. Severe Preeclampsia in the Setting of Myasthenia Gravis. Case reports in obstetrics and gynecology. 2017;2017:9204930.
    8. Sikka P, Joshi B, Aggarwal N, Suri V, Bhagat H. Distinguishing Myasthenia Exacerbation from Severe Preeclampsia: A Diagnostic and Therapeutic Challenge. Journal of clinical and diagnostic research : JCDR. 2015;9(8):Qd05-6.
    9. Ferrero S, Pretta S, Nicoletti A, Petrera P, Ragni N. Myasthenia gravis: management issues during pregnancy. European journal of obstetrics, gynecology, and reproductive biology. 2005;121(2):129-38.
    10. Klehmet J, Dudenhausen J, Meisel A. Verlauf und Behandlung der Myasthenia gravis in der Schwangerschaft. Der Nervenarzt. 2010;81:956–62.
    11. Polizzi A, Huson SM, Vincent A. Teratogen update: maternal myasthenia gravis as a cause of congenital arthrogryposis. Teratology. 2000;62(5):332-41.
    12. EMA. Kalymin® (Pyridostigminbromid) - Fachinformation 2018 [Available from: https://www.fachinfo.de/api/fachinfo/pdf/009088.
    13. Bansal R, Goyal MK, Modi M. Management of myasthenia gravis during pregnancy. Indian journal of pharmacology. 2018;50(6):302-8.
    14. Hoff JM, Daltveit AK, Gilhus NE. Myasthenia gravis in pregnancy and birth: identifying risk factors, optimising care. European journal of neurology. 2007;14(1):38-43.
    15. Norwood F, Dhanjal M, Hill M, James N, Jungbluth H, Kyle P, et al. Myasthenia in pregnancy: best practice guidelines from a U.K. multispecialty working group. Journal of neurology, neurosurgery, and psychiatry. 2014;85(5):538-43.
    16. Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I, et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology. 2016;87(4):419-25.
    17. Williamson RA, Karp LE. Azathioprine teratogenicity: review of the literature and case report. Obstet Gynecol. 1981;58(2):247-50.
    18. Polifka JE, Friedman JM. Teratogen update: azathioprine and 6-mercaptopurine. Teratology. 2002;65(5):240-61.
    19. Clark JM. The mutagenicity of azathioprine in mice, Drosophila melanogaster and Neurospora crassa. Mutat Res. 1975;28(1):87-99.
    20. Ligumsky M, Badaan S, Lewis H, Meirow D. Effects of 6-mercaptopurine treatment on sperm production and reproductive performance: a study in male mice. Scand J Gastroenterol. 2005;40(4):444-9.
    21. EMA. Zytrim® (Azathioprin) - Fachinformation 2016 [Available from: https://www.fachinfo.de/api/fachinfo/pdf/005329.
    22. Natekar A, Pupco A, Bozzo P, Koren G. Safety of azathioprine use during pregnancy. Canadian family physician Medecin de famille canadien. 2011;57(12):1401-2.
    23. Alami Z, Agier MS, Ahid S, Vial T, Dautriche A, Lagarce L, et al. Pregnancy outcome following in utero exposure to azathioprine: A French comparative observational study. Therapie. 2018;73(3):199-207.
    24. Mozaffari S, Abdolghaffari AH, Nikfar S, Abdollahi M. Pregnancy outcomes in women with inflammatory bowel disease following exposure to thiopurines and antitumor necrosis factor drugs: a systematic review with meta-analysis. Hum Exp Toxicol. 2015;34(5):445-59.
    25. Naqvi R, Noor H, Ambareen S, Khan H, Haider A, Jafri N, et al. Outcome of Pregnancy in Renal Allograft Recipients: SIUT Experience. Transplantation Proceedings. 2006;38(7):2001-2.
    26. Nørgård B, Fonager K, Pedersen L, Jacobsen BA, Sørensen HT. Birth outcome in women exposed to 5-aminosalicylic acid during pregnancy: a Danish cohort study. Gut. 2003;52(2):243-7.
    27. Francella A, Dyan A, Bodian C, Rubin P, Chapman M, Present DH. The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology. 2003;124(1):9-17.
    28. Moskovitz DN, Bodian C, Chapman ML, Marion JF, Rubin PH, Scherl E, et al. The Effect on the Fetus of Medications Used to Treat Pregnant Inflammatory Bowel-Disease Patients. American Journal Of Gastroenterology. 2004;99:656.
    29. Coelho J, Beaugerie L, Colombel JF, Hébuterne X, Lerebours E, Lémann M, et al. Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME Study. Gut. 2011;60(2):198-203.
    30. Akbari M, Shah S, Velayos FS, Mahadevan U, Cheifetz AS. Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19(1):15-22.
    31. Cleary BJ, Kallen B. Early pregnancy azathioprine use and pregnancy outcomes. Birth Defects Res A Clin Mol Teratol. 2009;85(7):647-54.
    32. Goldstein LH, Dolinsky G, Greenberg R, Schaefer C, Cohen-Kerem R, Diav-Citrin O, et al. Pregnancy outcome of women exposed to azathioprine during pregnancy. Birth Defects Research Part A: Clinical and Molecular Teratology. 2007;79(10):696-701.
    33. Saarikoski S, Seppala M. Immunosuppression during pregnancy: transmission of azathioprine and its metabolites from the mother to the fetus. Am J Obstet Gynecol. 1973;115(8):1100-6.
    34. de Boer NKH, Jarbandhan SVA, de Graaf P, Mulder CJJ, van Elburg RM, van Bodegraven AA. Azathioprine Use During Pregnancy: Unexpected Intrauterine Exposure to Metabolites. The American Journal Of Gastroenterology. 2006;101:1390.
    35. Flint JD, Mouyis M, I. G. A Systematic Review of the Impact of Anti-Rheumatic Drugs upon Male Fertility and Paternal Exposure Peri-Conception [abstract]. Arthritis Rheumatol. 2017;69(suppl 10).
    36. Dejaco C, Mittermaier C, Reinisch W, Gasche C, Waldhoer T, Strohmer H, et al. Azathioprine treatment and male fertility in inflammatory bowel disease. Gastroenterology. 2001;121(5):1048-53.
    37. Sau A, Clarke S, Bass J, Kaiser A, Marinaki A, Nelson-Piercy C. Azathioprine and breastfeeding—is it safe? BJOG: An International Journal of Obstetrics & Gynaecology. 2007;114(4):498-501.
    38. Christensen LA, Dahlerup JF, Nielsen MJ, Fallingborg JF, Schmiegelow K. Azathioprine treatment during lactation. Alimentary Pharmacology & Therapeutics. 2008;28(10):1209-13.
    39. Blanford AT, Pearson Murphy BE. In vitro metabolism of prednisolone, dexamethasone, betamethasone, and cortisol by the human placenta. American Journal of Obstetrics and Gynecology. 1977;127(3):264-7.
    40. Kemp MW, Newnham JP, Challis JG, Jobe AH, Stock SJ. The clinical use of corticosteroids in pregnancy. Hum Reprod Update. 2016;22(2):240-59.
    41. Walker BE. Induction of cleft palate in rabbits by several glucocorticoids. Proc Soc Exp Biol Med. 1967;125(4):1281-4.
    42. Pinsky L, DiGeorge AM. Cleft Palate in the Mouse: A Teratogenic Index of Glucocorticoid Potency. Science. 1965;147(3656):402-3.
    43. Shah RM, Chaudhry AP. Hydrocortisone-induced cleft palate in hamsters. Teratology. 1973;7(2):191-4.
    44. Carmichael SL, Shaw GM, Yang W, Abrams B, Lammer EJ. Maternal Stressful Life Events and Risks of Birth Defects. Epidemiology (Cambridge, Mass). 2007;18(3):356-61.
    45. Park-Wyllie L, Mazzotta P, Pastuszak A, Moretti ME, Beique L, Hunnisett L, et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology. 2000;62(6):385-92.
    46. Pradat P, Robert-Gnansia E, Di Tanna GL, Rosano A, Lisi A, Mastroiacovo P. First trimester exposure to corticosteroids and oral clefts. Birth Defects Research Part A: Clinical and Molecular Teratology. 2003;67(12):968-70.
    47. Kallen B, Olausson PO. No increased risk of infant hypospadias after maternal use of loratadine in early pregnancy. Int J Med Sci. 2006;3(3):106-7.
    48. Hviid A, Mølgaard-Nielsen D. Corticosteroid use during pregnancy and risk of orofacial clefts. CMAJ : Canadian Medical Association Journal. 2011;183(7):796-804.
    49. Skuladottir H, Wilcox AJ, Ma C, Lammer EJ, Rasmussen SA, Werler MM, et al. Corticosteroid use and risk of orofacial clefts. Birth Defects Research Part A, Clinical and Molecular Teratology. 2014;100(6):499-506.
    50. Tegethoff M, Greene N, Olsen J, Schaffner E, Meinlschmidt G. Inhaled glucocorticoids during pregnancy and offspring pediatric diseases: a national cohort study. Am J Respir Crit Care Med. 2012;185(5):557-63.
    51. Ali Khan A, Rodriguez A, Kaakinen M, Pouta A, Hartikainen A-L, Jarvelin M-R. Does in utero exposure to synthetic glucocorticoids influence birthweight, head circumference and birth length? A systematic review of current evidence in humans. Paediatric and Perinatal Epidemiology. 2011;25(1):20-36.
    52. Katz FH, Duncan BR. Letter: Entry of prednisone into human milk. N Engl J Med. 1975;293(22):1154.
    53. Öst L, Wettrell G, Björkhem I, Rane A. Prednisolone excretion in human milk. The Journal of Pediatrics. 1985;106(6):1008-11.
    54. Boz C, Terzi M, Zengin Karahan S, Sen S, Sarac Y, Emrah Mavis M. Safety of IV pulse methylprednisolone therapy during breastfeeding in patients with multiple sclerosis. Multiple Sclerosis Journal. 2018;24(9):1205-11.
    55. Bullingham RES, Nicholls AJ, Kamm BR. Clinical Pharmacokinetics of Mycophenolate Mofetil. Clinical Pharmacokinetics. 1998;34(6):429-55.
    56. EMA. Cellcept® (mycophenolate mophetile) - EPAR Summary of product characteristics 2018 [Available from: https://www.ema.europa.eu/en/documents/product-information/cellcept-epar-product-information_en.pdf].
    57. Klieger-Grossmann C, Chitayat D, Lavign S, Kao K, Garcia-Bournissen F, Quinn D, et al. Prenatal Exposure to Mycophenolate Mofetil: An Updated Estimate. Journal of Obstetrics and Gynaecology Canada. 2010;32(8):794-7.
    58. Anderka MT, Lin AE, Abuelo DN, Mitchell AA, Rasmussen SA. Reviewing the evidence for mycophenolate mofetil as a new teratogen: Case report and review of the literature. American Journal of Medical Genetics Part A. 2009;149A(6):1241-8.
    59. Perez-Aytes A, Marin-Reina P, Boso V, Ledo A, Carey JC, Vento M. Mycophenolate mofetil embryopathy: A newly recognized teratogenic syndrome. European Journal of Medical Genetics. 2017;60(1):16-21.
    60. Hoeltzenbein M, Elefant E, Vial T, Finkel-Pekarsky V, Stephens S, Clementi M, et al. Teratogenicity of mycophenolate confirmed in a prospective study of the European Network of Teratology Information Services. American Journal of Medical Genetics Part A. 2012;158A(3):588-96.
    61. Jones A, Clary MJ, McDermott E, Coscia LA, Constantinescu S, Moritz MJ, et al. Outcomes of Pregnancies Fathered by Solid-Organ Transplant Recipients Exposed to Mycophenolic Acid Products. Progress in Transplantation. 2013;23(2):153-7.
    62. Midtvedt K, Bergan S, Reisæter AV, Vikse BE, Åsberg A. Exposure to Mycophenolate and Fatherhood. Transplantation. 2017;101(7):e214-e7.
    63. Constantinescu S, Pai A, Coscia LA, Davison JM, Moritz MJ, Armenti VT. Breast-feeding after transplantation. Best Practice & Research Clinical Obstetrics & Gynaecology. 2014;28(8):1163-73.
    64. EMA. Sandimmun® (Ciclosporin) - Fachinformation 2015 [Available from: https://www.fachinfo.de/api/fachinfo/pdf/001861].
    65. Puchner A, Grochenig HP, Sautner J, Helmy-Bader Y, Juch H, Reinisch S, et al. Immunosuppressives and biologics during pregnancy and lactation : A consensus report issued by the Austrian Societies of Gastroenterology and Hepatology and Rheumatology and Rehabilitation. Wiener klinische Wochenschrift. 2019;131(1-2):29-44.
    66. Lamarque V, Leleu MF, Monka C, Krupp P. Analysis of 629 pregnancy outcomes in transplant recipients treated with Sandimmun. Transplantation proceedings. 1997;29(5):2480.
    67. EMA. Advagraf® (Tacrolimus) - EPAR Summary of product characteristics 2019 [Available from: https://www.ema.europa.eu/en/documents/product-information/advagraf-epar-product-information_en.pdf].
    68. Jain A, Venkataramanan R, Fung JJ, Gartner JC, Lever J, Balan V, et al. Pregnancy after liver transplantation under tacrolimus. Transplantation. 1997;64(4):559-65.
    69. Jain AB, Reyes J, Marcos A, Mazariegos G, Eghtesad B, Fontes PA, et al. Pregnancy after liver transplantation with tacrolimus immunosuppression: a single center's experience update at 13 years. Transplantation. 2003;76(5):827-32.
    70. Mouyis M, Flint JD, Giles IP. Safety of anti-rheumatic drugs in men trying to conceive: A systematic review and analysis of published evidence. Seminars in arthritis and rheumatism. 2019;48(5):911-20.
    71. Bannwarth B, Pehourcq F, Schaeverbeke T, Dehais J. Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. Clin Pharmacokinet. 1996;30(3):194-210.
    72. Feldkamp M, Carey JC. Clinical teratology counseling and consultation case report: low dose methotrexate exposure in the early weeks of pregnancy. Teratology. 1993;47(6):533-9.
    73. Hyoun SC, Običan SG, Scialli AR. Teratogen update: Methotrexate. Birth Defects Research Part A: Clinical and Molecular Teratology. 2012;94(4):187-207.
    74. Gutierrez JC, Hwang K. The toxicity of methotrexate in male fertility and paternal teratogenicity. Expert Opinion on Drug Metabolism & Toxicology. 2017;13(1):51-8.
    75. Eck LK, Jensen TB, Mastrogiannis D, Torp-Pedersen A, Askaa B, Nielsen TK, et al. Risk of Adverse Pregnancy Outcome After Paternal Exposure to Methotrexate Within 90 Days Before Pregnancy. Obstetrics & Gynecology. 2017;129(4):707-14.
    76. Johns DG, Rutherford LD, Leighton PC, Vogel CL. Secretion of methotrexate into human milk. American Journal of Obstetrics and Gynecology. 1972;112(7):978-80.
    77. Thorne JC, Nadarajah T, Moretti M, Ito S. Methotrexate Use in a Breastfeeding Patient with Rheumatoid Arthritis. The Journal of Rheumatology. 2014;41(11):2332-.
    78. Brinker KA, Silk HJ. Common variable immune deficiency and treatment with intravenous immunoglobulin during pregnancy. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology. 2012;108(6):464-5.
    79. Omwandho CO, Gruessner SE, Roberts TK, Tinneberg HR. Intravenous immunoglobulin (IVIG): modes of action in the clinical management of recurrent pregnancy loss (RPL) and selected autoimmune disorders. Clinical chemistry and laboratory medicine. 2004;42(4):359-70.
    80. Ross LJ. Dermatoglyphics in offspring of women given gamma globulin prophylaxis during pregnancy. Teratology. 1996;53(5):285-91.
    81. Gamez J, Salvado M, Casellas M, Manrique S, Castillo F. Intravenous immunoglobulin as monotherapy for myasthenia gravis during pregnancy. Journal of the neurological sciences. 2017;383:118-22.
    82. Immune Globulin. Drugs and Lactation Database (LactMed). Bethesda (MD): National Library of Medicine (US); 2006.
    83. Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. Clinical & developmental immunology. 2012;2012:985646.
    84. Malek A, Sager R, Kuhn P, Nicolaides KH, Schneider H. Evolution of maternofetal transport of immunoglobulins during human pregnancy. American journal of reproductive immunology (New York, NY : 1989). 1996;36(5):248-55.
    85. EMA. MabThera® (rituximab) - EPAR Summary of product characteristics 2009 [updated 02 Aug 2016. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000165/WC500025821.pdf].
    86. Chakravarty EF, Murray ER, Kelman A, Farmer P. Pregnancy outcomes after maternal exposure to rituximab. Blood. 2011;117(5):1499-506.
    87. Das G, Damotte V, Gelfand JM, Bevan C, Cree BAC, Do L, et al. Rituximab before and during pregnancy: A systematic review, and a case series in MS and NMOSD. Neurology(R) neuroimmunology & neuroinflammation. 2018;5(3):e453-e.
    88. Grunewald S, Jank A. New systemic agents in dermatology with respect to fertility, pregnancy, and lactation. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2015;13(4):277-90.
    89. Bragnes Y, Boshuizen R, de Vries A, Lexberg Å, Østensen M. Low level of Rituximab in human breast milk in a patient treated during lactation. Rheumatology. 2017;56(6):1047-8.
    90. Thone J, Thiel S, Gold R, Hellwig K. Treatment of multiple sclerosis during pregnancy - safety considerations. Expert Opin Drug Saf. 2017;16(5):523-34.
    91. EMA. Soliris® (Eculizumab) - EPAR Summary of product characteristics 2018 [updated 20. September 2018. Available from: https://www.ema.europa.eu/en/documents/product-information/soliris-epar-product-information_en.pdf].
    92. Sarno L, Tufano A, Maruotti GM, Martinelli P, Balletta MM, Russo D. Eculizumab in pregnancy: a narrative overview. Journal of Nephrology. 2019;32(1):17-25.
    93. Kelly RJ, Höchsmann B, Szer J, Kulasekararaj A, de Guibert S, Röth A, et al. Eculizumab in Pregnant Patients with Paroxysmal Nocturnal Hemoglobinuria. New England Journal of Medicine. 2015;373(11):1032-9.
    94. Hallstensen RF, Bergseth G, Foss S, Jæger S, Gedde-Dahl T, Holt J, et al. Eculizumab treatment during pregnancy does not affect the complement system activity of the newborn. Immunobiology. 2015;220(4):452-9.
    95. Kelly R, Arnold L, Richards S, Hill A, Bomken C, Hanley J, et al. The management of pregnancy in paroxysmal nocturnal haemoglobinuria on long term eculizumab. British Journal of Haematology. 2010;149(3):446-50.
    96. Watson WJ, Katz VL, Bowes WA, Jr. Plasmapheresis during pregnancy. Obstet Gynecol. 1990;76(3 Pt 1):451-7.
    97. Hoffmann F, Kraft A, Heigl F, Mauch E, Koehler J, Harms L, et al. Tryptophan immunoadsorption during pregnancy and breastfeeding in patients with acute relapse of multiple sclerosis and neuromyelitis optica. Therapeutic Advances in Neurological Disorders. 2018;11:1756286418774973.
    98. Cox JL, Koepsell SA, Shunkwiler SM. Therapeutic plasma exchange and pregnancy: A case report and guidelines for performing plasma exchange in a pregnant patient. Journal of Clinical Apheresis. 2017;32(3):191-5.
    99. Embryotox.de. 2021. Embryotox - Arzneimittelsicherheit in Schwangerschaft und Stillzeit: Prednisolon.[online]Available at: https://www.embryotox.de/arzneimittel/details/prednisolon/ [Accessed 22 March 2021].
    100. EMA. Ultomyris® (Ravulizumab) - Fachinformation 2023 [Available from: https://www.ema.europa.eu/en/documents/product-information/ultomiris-epar-product-information_de.pdf]
    101. EMA. Vyvgart® (Efgartigimod) - Fachinformation 2022 [Available from: https://www.ema.europa.eu/en/documents/product-information/vyvgart-epar-product-information_en.pdf]
    102. Philip O. Anderson.Monoclonal Antibodies During Breastfeeding.Breastfeeding Medicine.Aug 2021.591-593. http://doi.org/10.1089/bfm.2021.0110
    103. Krysko KM, Dobson R, Alroughani R, Amato MP, Bove R, Ciplea AI, Fragoso Y, Houtchens M, Jokubaitis VG, Magyari M, Abdelnasser A, Padma V, Thiel S, Tintore M, Vukusic S, Hellwig K. Family planning considerations in people with multiple sclerosis. Lancet Neurol. 2023 Apr;22(4):350-366. doi: 10.1016/S1474-4422(22)00426-4. PMID: 36931808
Impressum · Datenschutz